OmniAb, Inc. (OABI) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. OmniAb, Inc. is a biotechnology company licensing discovery research technology, including its AI-powered xPloration platform and Biological Intelligence™, to pharmaceutical and biotech partners for antibody discovery. The company operates as a single reportable segment and is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Total Revenue | $13.4 million | $27.8 million | N/A |
| Net Loss | $(5.9) million | $(13.6) million | N/A |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.11) | N/A |
| Operating Cash Flow | N/A | $(2.2) million (Used) | N/A |
| Cash & Short-Term Investments | N/A | N/A | $52.0 million |
| Total Assets | N/A | N/A | $290.3 million |
| Total Liabilities | N/A | N/A | $30.0 million |
| Stockholders' Equity | N/A | N/A | $260.3 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 244% year-over-year for the quarter and 246% for the six-month period. This was driven primarily by a 666% increase in license and milestone revenue (Q3) and a 560% increase (YTD), attributed to milestone achievements.
- Expense Reduction: Research and Development (R&D) expenses decreased 12% (Q3) and 18% (YTD), and General and Administrative (G&A) expenses decreased 13% (Q3) and 15% (YTD). Reductions were due to lower personnel costs following 2025 reorganizations and reduced facility costs.
- Impairment Charge: Amortization of intangibles increased 41% YTD due to a $2.9 million impairment charge related to the discontinuation of legacy small molecule ion channel programs.
- Net Loss Improvement: Net loss narrowed significantly, decreasing 63% for the quarter and 60% for the six-month period compared to the prior year.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes existing cash, cash equivalents, and short-term investments ($52.0 million) are sufficient to fund operations for at least the next 12 months.
- Capital Resources: The company completed a $30.0 million private placement (PIPE) in August 2025. An "At-The-Market" (ATM) facility with $88.3 million remaining capacity is available, though no shares were sold under it in the first half of 2026.
- Warrants: Outstanding warrants (Public, Private, Forward Purchase, Backstop) are currently "out of the money" with an exercise price of $11.50, meaning no cash proceeds are expected from exercises in the near term.
- Risks: Future revenue is heavily dependent on partners' success in developing and commercializing therapies. The company faces risks related to the timing of milestones, regulatory approvals, and the need for potential future capital raises if cash flows are insufficient.
- Business Metrics: As of June 30, 2026, the company reported 110 active partners, 425 active programs, and 34 active clinical programs/approved products.
Investor Verification Checklist
- Milestone Sustainability: Verify the specific partners and programs driving the $18.3 million increase in milestone revenue to assess future recurring potential.
- Impairment Details: Review the full scope of the $2.9 million impairment charge on legacy ion channel assets to ensure no further write-downs are anticipated.
- Cash Burn Rate: Monitor the trend in operating cash flow usage ($2.2 million for six months) against the $52.0 million cash balance to validate the 12-month runway assertion.
- Warrant Redemption: Track the stock price relative to the $11.50 warrant exercise price, as redemption or exercise could impact share count and capital structure.
- Contingent Liabilities: Review the $0.965 million in contingent liabilities (Level 3 fair value) and the assumptions used for their valuation, as these can fluctuate based on partner program success.